Literature DB >> 8780540

Lobular neoplasia. Long term risk of breast cancer and relation to other factors.

C A Bodian1, K H Perzin, R Lattes.   

Abstract

BACKGROUND: Lobular neoplasia (LN), also known as lobular carcinoma in situ, is an incidental histologic finding in tissue removed at breast surgery. Patients with LN are known to be predisposed to develop invasive or intraductal carcinoma (CA). This study investigates factors that influence the cancer risk in LN patients.
METHODS: Analysis of data concerning long term follow-up (median: 18 yrs) of 236 patients with LN identified in a pathologic review of more than 2000 biopsy specimens with benign epithelial proliferative breast disease.
RESULTS: The probability of CA developing in either breast in long term survivors after a biopsy that contained LN was approximately 1/3, which is 5.4 times (95% CI: 4.2 - 7.0) the rate in the general population. The relative risk (RR) tended to decrease with increasing age at diagnosis, but was approximately doubled (RR: 1.8; 95% CI: 1.1-3.2) for patients with benign epithelial breast disease preceding their initial diagnosis of LN. CA risk remained markedly elevated for at least 20 years, and increased substantially if there was a second operation showing LN- from 4.9 (95% CI: 3.7-6.4) after a single operation with LN to 16.1 (95% CI: 6.9-31.8) after a second such operation.
CONCLUSIONS: LN is a marker of increased CA risk that is further exacerbated by episodes of preexisting benign breast epithelial proliferative changes, and that remains substantially elevated for many years.

Entities:  

Mesh:

Year:  1996        PMID: 8780540     DOI: 10.1002/(SICI)1097-0142(19960901)78:5<1024::AID-CNCR12>3.0.CO;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Multiplex genotype analysis of invasive carcinoma and accompanying proliferative lesions microdissected from breast tissue.

Authors:  X Cui; H Feiner; Z Lin; H Li
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

Review 2.  The basic pathology of human breast cancer.

Authors:  E Mallon; P Osin; N Nasiri; I Blain; B Howard; B Gusterson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-04       Impact factor: 2.673

3.  Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.

Authors:  Hans-Peter Sinn; Zeinab Elsawaf; Birgit Helmchen; Sebastian Aulmann
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

Review 4.  Suitable trial designs and cohorts for preventive breast cancer agents.

Authors:  Kathrin Strasser-Weippl; Paul E Goss
Journal:  Nat Rev Clin Oncol       Date:  2013-10-08       Impact factor: 66.675

5.  Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.

Authors:  Lauren J Taylor; Jennifer Steiman; Jessica R Schumacher; Lee G Wilke; Caprice C Greenberg; Heather B Neuman
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

Review 6.  Rating the risk factors for breast cancer.

Authors:  S Eva Singletary
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

7.  Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

Authors:  Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

8.  Assessing and managing breast cancer risk: clinical tools for advising patients.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2004-01-14

Review 9.  In situ breast cancer.

Authors:  R S Henry-Tillman; V S Klimberg
Journal:  Curr Treat Options Oncol       Date:  2000-08

Review 10.  Lobular carcinoma in situ: diagnostic criteria and molecular correlates.

Authors:  Anna Sokolova; Sunil R Lakhani
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.